No Data
No Data
Is Eli Lilly and Company (LLY) the Best Quality Stock to Invest in Now?
Eli Lilly Snaps Six Days of Losses
Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
Short Bets Against S&P 500 Healthcare Stock Rises in Feb; MRNA Stays Top Shorted
Anat Ashkenazi -- Barrons.com
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E